WallStreetZenWallStreetZen

NASDAQ: TCRX
Tscan Therapeutics Inc Stock

$7.94-0.36 (-4.34%)
Updated Mar 28, 2024
TCRX Price
$7.94
Fair Value Price
N/A
Market Cap
$380.18M
52 Week Low
$1.62
52 Week High
$9.00
P/E
-5.84x
P/B
2.52x
P/S
18.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.05M
Earnings
-$89.22M
Gross Margin
100%
Operating Margin
-406%
Profit Margin
-423.9%
Debt to Equity
0.8
Operating Cash Flow
-$61M
Beta
0.55
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TCRX Overview

TScan Therapeutics Incorporated is a preclinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for the treatment of cancer. TSC-100 and TSC-101 are intended to treat patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 are intended to treat solid tumors.The company was incorporated in 2018 and is headquartered in Waltham, MA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TCRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TCRX is good value based on its book value relative to its share price (2.52x), compared to the US Biotechnology industry average (6.21x)
P/B vs Industry Valuation
TCRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TCRX due diligence checks available for Premium users.

Be the first to know about important TCRX news, forecast changes, insider trades & much more!

TCRX News

Valuation

TCRX fair value

Fair Value of TCRX stock based on Discounted Cash Flow (DCF)
Price
$7.94
Fair Value
$0.00
Overvalued by
1,272,594.31%
TCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TCRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.84x
Industry
14.26x
Market
44.51x

TCRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.52x
Industry
6.21x
TCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TCRX's financial health

Profit margin

Revenue
$7.2M
Net Income
-$19.6M
Profit Margin
-272%
TCRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$272.1M
Liabilities
$121.3M
Debt to equity
0.8
TCRX's short-term assets ($194.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRX's short-term assets ($194.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.8M
Investing
$1.9M
Financing
$19.0k
TCRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TCRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TCRX$380.18M-4.34%-5.84x2.52x
RENB$380.72M-5.02%-3.79x8.73x
AKBA$383.15M-18.30%-6.54x-12.53x
PROK$376.12M+4.46%-2.88x-0.34x
THRD$384.34M-0.32%-12.10x1.43x

Tscan Therapeutics Stock FAQ

What is Tscan Therapeutics's quote symbol?

(NASDAQ: TCRX) Tscan Therapeutics trades on the NASDAQ under the ticker symbol TCRX. Tscan Therapeutics stock quotes can also be displayed as NASDAQ: TCRX.

If you're new to stock investing, here's how to buy Tscan Therapeutics stock.

What is the 52 week high and low for Tscan Therapeutics (NASDAQ: TCRX)?

(NASDAQ: TCRX) Tscan Therapeutics's 52-week high was $9.00, and its 52-week low was $1.62. It is currently -11.78% from its 52-week high and 390.12% from its 52-week low.

How much is Tscan Therapeutics stock worth today?

(NASDAQ: TCRX) Tscan Therapeutics currently has 47,882,196 outstanding shares. With Tscan Therapeutics stock trading at $7.94 per share, the total value of Tscan Therapeutics stock (market capitalization) is $380.18M.

Tscan Therapeutics stock was originally listed at a price of $10.01 in Jul 19, 2021. If you had invested in Tscan Therapeutics stock at $10.01, your return over the last 2 years would have been -20.68%, for an annualized return of -10.94% (not including any dividends or dividend reinvestments).

How much is Tscan Therapeutics's stock price per share?

(NASDAQ: TCRX) Tscan Therapeutics stock price per share is $7.94 today (as of Mar 28, 2024).

What is Tscan Therapeutics's Market Cap?

(NASDAQ: TCRX) Tscan Therapeutics's market cap is $380.18M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tscan Therapeutics's market cap is calculated by multiplying TCRX's current stock price of $7.94 by TCRX's total outstanding shares of 47,882,196.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.